CN101654479A - 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法 - Google Patents

哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法 Download PDF

Info

Publication number
CN101654479A
CN101654479A CN200910159449A CN200910159449A CN101654479A CN 101654479 A CN101654479 A CN 101654479A CN 200910159449 A CN200910159449 A CN 200910159449A CN 200910159449 A CN200910159449 A CN 200910159449A CN 101654479 A CN101654479 A CN 101654479A
Authority
CN
China
Prior art keywords
polypeptide
ser
leu
seq
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200910159449A
Other languages
English (en)
Chinese (zh)
Inventor
M·基里卡
R·A·卡斯特莱恩
K·W·穆尔
C·L·帕哈姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22753958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101654479(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101654479A publication Critical patent/CN101654479A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
CN200910159449A 2000-05-10 2001-05-10 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法 Pending CN101654479A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20342600P 2000-05-10 2000-05-10
US60/203426 2000-05-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA018124119A Division CN1575337A (zh) 2000-05-10 2001-05-10 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法

Publications (1)

Publication Number Publication Date
CN101654479A true CN101654479A (zh) 2010-02-24

Family

ID=22753958

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA018124119A Pending CN1575337A (zh) 2000-05-10 2001-05-10 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法
CN200910159449A Pending CN101654479A (zh) 2000-05-10 2001-05-10 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CNA018124119A Pending CN1575337A (zh) 2000-05-10 2001-05-10 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法

Country Status (25)

Country Link
US (7) US6756481B2 (https=)
EP (3) EP1287130B2 (https=)
JP (6) JP5073909B2 (https=)
KR (1) KR100869621B1 (https=)
CN (2) CN1575337A (https=)
AT (1) ATE396264T1 (https=)
AU (2) AU2001261351B2 (https=)
CA (1) CA2408571C (https=)
CY (1) CY1108545T1 (https=)
CZ (1) CZ304022B6 (https=)
DE (1) DE60134136D1 (https=)
DK (1) DK1287130T3 (https=)
ES (1) ES2307618T3 (https=)
HK (1) HK1049862B (https=)
HU (1) HUP0302339A3 (https=)
IL (2) IL152414A0 (https=)
MX (1) MXPA02011081A (https=)
NO (2) NO331408B1 (https=)
NZ (1) NZ522146A (https=)
PL (1) PL209128B1 (https=)
PT (1) PT1287130E (https=)
SI (1) SI1287130T1 (https=)
SK (1) SK287984B6 (https=)
WO (1) WO2001085790A2 (https=)
ZA (1) ZA200208795B (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082734A1 (en) * 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
EP2325316B8 (en) * 1999-06-02 2017-04-19 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, NR10
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
US7422743B2 (en) 2000-05-10 2008-09-09 Schering Corporation Mammalian receptor protein DCRS5;methods of treatment
US6756481B2 (en) * 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions
WO2004042009A2 (en) * 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
WO2004058178A2 (en) 2002-12-23 2004-07-15 Schering Corporation Uses of mammalian cytokine; related reagents
US20040219150A1 (en) * 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
US7282204B2 (en) * 2003-03-10 2007-10-16 Schering Corporation Uses of IL-23 agonists and antagonists; related reagents
CN101052726A (zh) 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
CN1942201B (zh) * 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法；相关试剂
BRPI0510617A (pt) 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
AR051444A1 (es) * 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7820168B2 (en) * 2004-12-20 2010-10-26 Schering Corporation Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
SI2452694T1 (sl) 2005-06-30 2019-05-31 Janssen Biotech, Inc. Protitelesa proti-IL-23, sestavki in postopki uporabe
HUE034269T2 (en) 2005-12-29 2018-02-28 Janssen Biotech Inc Human anti-IL-23 antibodies, preparations, methods and applications
ES2429407T3 (es) 2006-06-08 2013-11-14 Chugai Seiyaku Kabushiki Kaisha Agente preventivo o remedio para enfermedades inflamatorias
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
CA2679400A1 (en) * 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
NZ579251A (en) 2007-02-28 2012-06-29 Schering Corp Engineered anti-il-23r antibodies
CA2708065C (en) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
US20110158992A1 (en) * 2008-08-27 2011-06-30 Schering Corporation Engineered Anti-IL-23R Antibodies
JP2012524524A (ja) * 2009-04-27 2012-10-18 ノバルティス アーゲー ＩＬ−１２レセプターβ１サブユニットに特異的な治療用抗体の組成物および使用方法
CN102458437B (zh) 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
MX2019000046A (es) 2010-11-04 2023-10-05 Boehringer Ingelheim Int Anticuerpos anti-il-23.
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
EP3708679A1 (en) 2014-07-24 2020-09-16 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
EA202193002A2 (ru) 2014-09-03 2022-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Соединение, нацеленное на ил-23a и фно-альфа, и его применение
AU2016215535B2 (en) 2015-02-04 2021-09-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
JP7805788B2 (ja) 2019-05-23 2026-01-26 ヤンセン バイオテツク，インコーポレーテツド Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法
TW202535466A (zh) 2019-09-09 2025-09-16 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
IL298389A (en) 2020-05-21 2023-01-01 Janssen Biotech Inc Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073451A1 (en) * 1999-06-01 2000-12-07 Schering Corporation Mammalian receptor proteins; related reagents and methods

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (https=) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4659678A (en) 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
US5888774A (en) 1994-12-19 1999-03-30 Cangene Corporation Recombinant DNA molecules and expression vectors for erythropoietin
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
JPH11273358A (ja) 1998-03-26 1999-10-08 Kawasaki Steel Corp 半導体記憶装置
US20030082734A1 (en) 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
AU780163B2 (en) * 1999-09-09 2005-03-03 Merck Sharp & Dohme Corp. Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
AU7445900A (en) * 1999-09-27 2001-04-30 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
JP2008099690A (ja) 1999-09-27 2008-05-01 Chugai Pharmaceut Co Ltd 新規ヘモポエチン受容体蛋白質、ｎｒ１２
US6756481B2 (en) * 2000-05-10 2004-06-29 Schering Corporation IL-23 receptor binding compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000073451A1 (en) * 1999-06-01 2000-12-07 Schering Corporation Mammalian receptor proteins; related reagents and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG YOU WU 等: "Biological function and distribution of human interleukin-12 receptor β chain", 《EUR.J.IMMUNOL.》 *
D.H.PRESKY 等: "A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits.", 《PROC.NAL.ACAD.SCI.U.S.A.》 *
LOK,S.,等: "AF178684.1", 《GENBANK》 *

Also Published As

Publication number Publication date
NO20111147L (no) 2003-01-10
JP2008273961A (ja) 2008-11-13
JP2012187111A (ja) 2012-10-04
US20050100917A1 (en) 2005-05-12
ES2307618T3 (es) 2008-12-01
KR100869621B1 (ko) 2008-11-21
AU6135101A (en) 2001-11-20
CA2408571A1 (en) 2001-11-15
ATE396264T1 (de) 2008-06-15
US6756481B2 (en) 2004-06-29
JP2015057396A (ja) 2015-03-26
WO2001085790A2 (en) 2001-11-15
DE60134136D1 (de) 2008-07-03
SK287984B6 (sk) 2012-08-06
DK1287130T3 (da) 2008-09-01
CZ304022B6 (cs) 2013-08-28
US8110378B2 (en) 2012-02-07
PL365177A1 (en) 2004-12-27
US7411041B2 (en) 2008-08-12
US20110243842A1 (en) 2011-10-06
SK15742002A3 (sk) 2003-03-04
MXPA02011081A (es) 2003-03-10
KR20020092472A (ko) 2002-12-11
US20120121601A1 (en) 2012-05-17
HK1049862B (en) 2008-08-01
HUP0302339A2 (hu) 2003-10-28
US20090060865A1 (en) 2009-03-05
EP1287130B2 (en) 2017-07-26
HK1049862A1 (en) 2003-05-30
NO20025354D0 (no) 2002-11-08
CA2408571C (en) 2014-04-29
CZ20023698A3 (cs) 2003-04-16
CN1575337A (zh) 2005-02-02
IL152414A0 (en) 2003-05-29
AU2001261351B2 (en) 2007-03-01
PL209128B1 (pl) 2011-07-29
HUP0302339A3 (en) 2011-01-28
EP2275548A1 (en) 2011-01-19
NO331408B1 (no) 2011-12-19
EP1918377B1 (en) 2013-12-04
JP2003532408A (ja) 2003-11-05
US7510853B2 (en) 2009-03-31
US20050100918A1 (en) 2005-05-12
WO2001085790A3 (en) 2002-07-18
NZ522146A (en) 2004-10-29
PT1287130E (pt) 2008-09-01
SI1287130T1 (sl) 2008-08-31
CY1108545T1 (el) 2014-04-09
EP1287130A2 (en) 2003-03-05
JP2012070740A (ja) 2012-04-12
IL152414A (en) 2010-05-31
EP1918377A1 (en) 2008-05-07
US7964703B2 (en) 2011-06-21
US7749718B2 (en) 2010-07-06
EP1287130B1 (en) 2008-05-21
US20030017617A1 (en) 2003-01-23
ZA200208795B (en) 2004-02-09
JP5073909B2 (ja) 2012-11-14
US20100261273A1 (en) 2010-10-14
JP2015110576A (ja) 2015-06-18
NO20025354L (no) 2003-01-10

Similar Documents

Publication Publication Date Title
JP5073909B2 (ja) 哺乳動物レセプタータンパク質；関連する試薬および方法
AU2001261351A1 (en) Mammalian receptor proteins; related reagents and methods
JP2015007129A (ja) 哺乳動物レセプタータンパク質；関連する試薬および方法
WO1999040195A1 (en) Mammalian receptor proteins; related reagents and methods
AU2007202362B2 (en) Mammalian receptor proteins; related reagents and methods
HK1152072A (en) Mammalian cytokine receptor subunit proteins, related reagents and methods
HK1117192A (en) Mammalian cytokine receptor subunit proteins, related reagents and methods

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: new jersey

Applicant after: Schering Corporation

Address before: new jersey

Applicant before: SCHERING CORP (US)

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: SCHERING CORP (US) TO: MSD CORP.

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20100224